Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Alembic Pharma Q4 posts net profit of Rs 93.79 crore

      Alembic Pharma Q4 posts net profit of Rs 93.79 crore

      Ruby Khatun Khatun18 May 2018 9:45 AM IST
      New Delhi: Drug firm Alembic Pharmaceuticals reported a consolidated net profit of Rs 93.79 crore for the quarter ended March 31, 2018.The company had...
      Suven Life Q4 net up 56 percent at Rs 62.5 crore

      Suven Life Q4 net up 56 percent at Rs 62.5 crore

      Ruby Khatun Khatun18 May 2018 9:30 AM IST
      New Delhi: Drug firm Suven Life Sciences reported a 56 percent rise in standalone net profit to Rs 62.51 crore for the March quarter.It had posted a...
      Bengaluru: Illegally imported skin-whitening drugs worth Rs 13.5 lakh recovered

      Bengaluru: Illegally imported skin-whitening drugs worth Rs 13.5 lakh recovered

      Ruby Khatun Khatun17 May 2018 4:30 PM IST
      It is believed by the investigators that the drug is used for skin bleaching through unethical medical practices in cosmetology clinics and beauty...
      Dr Lal PathLabs Q4 net up 27 percent at Rs 40 crore

      Dr Lal PathLabs Q4 net up 27 percent at Rs 40 crore

      Ruby Khatun Khatun17 May 2018 11:00 AM IST
      New Delhi: Diagnostic chain Dr Lal PathLabs reported 27.21 percent rise in consolidated net profit to Rs 40.2 crore for the quarter ended March 31,...
      Granules India gets EIR from USFDA for Telangana facility

      Granules India gets EIR from USFDA for Telangana facility

      Ruby Khatun Khatun17 May 2018 10:30 AM IST
      New Delhi: Pharma firm Granules India on Wednesday said the US health regulator has issued Establishment Inspection Report (EIR) after an audit of its...
      Glenmark Pharma launches generic version of asthma drug in Denmark

      Glenmark Pharma launches generic version of asthma drug in Denmark

      Ruby Khatun Khatun17 May 2018 10:00 AM IST
      New Delhi: Glenmark Pharmaceuticals Europe Ltd has launched a generic version of Seretide Accuhaler, used to treat asthma, in Denmark.The product was...
      Merck KGaAs lung cancer drugs show promise in early-stage trials

      Merck KGaA's lung cancer drugs show promise in early-stage trials

      Ruby Khatun Khatun17 May 2018 9:45 AM IST
      FRANKFURT: Germany’s Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially...
      6 US states accuse opioid maker Purdue of fueling overdoses

      6 US states accuse opioid maker Purdue of fueling overdoses

      Ruby Khatun Khatun17 May 2018 9:30 AM IST
      LAS VEGAS: Six U.S. states on Tuesday sued the maker of the opioid OxyContin of using deceptive marketing to boost drug sales that fueled opioid...
      Lupin posts Rs 783.5 crore net loss in Q4 due to one-time impairment

      Lupin posts Rs 783.5 crore net loss in Q4 due to one-time impairment

      Ruby Khatun Khatun16 May 2018 11:00 AM IST
      New Delhi: Drug major Lupin reported a consolidated net loss of Rs 783.54 crore for the quarter ended March 31, 2018, hit by one-time impairment on...
      Jubilant Life gets USFDA nod for Niacin extended release tablets

      Jubilant Life gets USFDA nod for Niacin extended release tablets

      Ruby Khatun Khatun16 May 2018 10:35 AM IST
      New Delhi: Jubilant Life Sciences Ltd said it has received the final approval from USFDA for its generic Niacin extended-release tablets used for...
      Netmeds appoints MS Dhoni as brand ambassador

      Netmeds appoints MS Dhoni as brand ambassador

      Ruby Khatun Khatun16 May 2018 10:15 AM IST
      New Delhi: Online pharmacy Netmeds said it has appointed cricketer Mahendra Singh Dhoni as its brand ambassador.Commenting on the development, Netmeds...
      April exports rise 5.17 percent to USD 25.91 billion on pharma, engineering

      April exports rise 5.17 percent to USD 25.91 billion on pharma, engineering

      Ruby Khatun Khatun16 May 2018 9:45 AM IST
      New Delhi: Exports grew by 5.17 percent to USD 25.91 billion in April compared to the same month last year on account of the healthy performance by...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok